Menu Search
Equities

Qualigen Therapeutics Inc

7R9:DUS

Qualigen Therapeutics Inc

Actions
  • Price (EUR)0.2540
  • Today's Change-0.016 / -5.93%
  • Shares traded1.00
  • 1 Year change-71.40%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 18:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.

  • Revenue in USD (TTM)0.00
  • Net income in USD-12.48m
  • Incorporated2008
  • Employees4.00
  • Location
    Qualigen Therapeutics Inc1880 Century Park E Ste 1000LOS ANGELES 90067-1623United StatesUSA
  • Phone+1 (310) 203-1000
  • Fax+1 (310) 919-1600
  • Websitehttps://www.qualigeninc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.